Developer docs
API playgroundTry for free, no card

Search company profiles

Yamo Pharmaceuticals

Full company profile

uuid0008yny

Namestring
Yamo Pharmaceuticals
Legal namestring
Yamo Pharmaceuticals
Websiteurl
yamopharma.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Yamo Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in New York, NY. The company is developing L1-79, an investigational oral, twice-daily selective tyrosine hydroxylase inhibitor designed to address core social-interaction deficits in Autism Spectrum Disorder (ASD) — an indication for which there are currently zero FDA-approved therapies. L1-79 modulates catecholamine pathways governing mood, attention, motor skills, and social behavior, and also addresses the hyperactive CNS state often observed in autism by engaging systems that regulate brain function and gut mechanisms implicated in some forms of the disorder. The molecule is described as the only drug in the world developed solely to treat the core symptoms of autism, distinguishing it from therapies that address only peripheral behaviors.

The company completed a multi-center, randomized, double-blind, placebo-controlled crossover Phase 2 study (Y202) in 58 adolescents and young adults with ASD in June 2024, reporting a 7.94-point improvement on the Vineland-3 Socialization Standard Score versus placebo (p=0.0115) — described as the most substantial reported to date with any ASD medication — with statistically significant gains on CGI-S and CGI-3P measures. L1-79 has received FDA Fast Track Designation, and the company is now preparing for Phase 3 development. Yamo is led by an experienced management team including CEO Chuck Bramlage (formerly of Pearl Therapeutics, Covidien, Valeant, Merck, GSK), CMO Dr. Tom Megerian, SVP Regulatory Dr. Tracy Fischer, and CAO Eugene Prahin, supported by a Scientific Advisory Board of prominent autism researchers from Duke, Harvard, Columbia, Emory, and other leading institutions.

Yamo operates as a pre-revenue company with no commercialized product. Its business model is traditional biopharmaceutical: upon FDA approval, the company intends to generate revenue through prescription sales of L1-79, distributed via specialty pharmacies and standard pharmaceutical supply chains targeting healthcare providers and ASD specialists. Marketing and stakeholder engagement are conducted primarily through peer-reviewed publications, scientific conference presentations (INSAR, CNS), and corporate communications, rather than consumer-facing channels. The company has a single disclosed funding event — a capital investment from The Autism Impact Fund in November 2021 — and has 1-10 employees, reflecting its lean, development-stage operational footprint.

Short descriptiontext

Yamo Pharmaceuticals is a clinical-stage biopharmaceutical company developing L1-79, an oral selective tyrosine hydroxylase inhibitor aimed at core social-interaction deficits in Autism Spectrum Disorder, currently advancing to Phase 3 with FDA Fast Track Designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autism pharmaceutical therapy, clinical-stage biopharmaceutical, selective tyrosine hydroxylase inhibitor, CNS drug development, autism spectrum disorder treatment
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Autism Spectrum Disorder Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Yamo Pharmaceuticals is a pre-revenue biopharmaceutical company developing L1-79 for Autism Spectrum Disorder. Once FDA approved, the company will generate revenue through prescription pharmaceutical sales of its oral, twice-daily treatment targeting core ASD symptoms. Revenue model will be traditional pharmaceutical product sales with potential for specialty pharmacy distribution.

yamopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Yamo Pharmaceuticals develops L1-79, an investigational oral twice-daily selective tyrosine hydroxylase inhibitor designed to address core social-interaction deficits in Autism Spectrum Disorder. The company is advancing this single-asset candidate through Phase 3 clinical development with FDA Fast Track Designation, targeting adolescents and young adults diagnosed with ASD.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 7.94-point Vineland-3 Socialization Standard Score improvement vs. placebo (p=0.0115) in Phase 2 study
+2 more records
Product overview1 text field

Yamo Pharmaceuticals is a single-product pharmaceutical company developing L1-79 as its lead and only product candidate. L1-79 is an investigational oral drug for Autism Spectrum Disorder (ASD) — the only therapy in the world solely focused on treating core autism symptoms rather than peripheral behaviors. The company operates with a pipeline model advancing L1-79 through clinical stages (Phase 2 complete, Phase 3 anticipated). No platform architecture, modules, or additional products are offered.

Product and service1 record
1L1-79
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty CNS pharmaceutical company with an ADHD and neurology portfolio. Comparable to Yamo as a late-stage clinical-to-commercial CNS developer with similar GTM motion into specialty prescribers, though Jazz has a broader marketed product base.

TypeDirect peer
Description

CNS specialty pharma focused on neurological and psychiatric disorders (pimavanserin franchise). Highly comparable business model — clinical-stage-to-commercial CNS developer with a similar specialty-pharmacy/specialist-prescriber launch approach and small-cap CNS positioning.

TypeDirect peer
Description

Clinical-stage-to-commercial CNS biotech (Auvelity, Sunosi). Closely analogous to Yamo in scale and trajectory: small team, single-disease focus, pivotal-trial-driven valuation, and a CNS regulatory pathway with Fast Track/priority review experience.

TypeDirect peer
Description

Clinical-stage CNS biotech with FDA-approved Zurzuvae (postpartum depression) and a pipeline focused on neurological/psychiatric indications. Comparable as a CNS-pure-play clinical developer facing similar subjective-endpoint and CNS launch challenges.

TypeDirect peer
Description

Specialty CNS pharma with ADHD and neurology franchises. Comparable commercial motion (specialty physician sales, specialty pharmacy distribution) and life-cycle trajectory from clinical CNS developer to CNS specialty commercial player.

TypeDirect peer
Description

Clinical-stage CNS biotech with a pipeline of neuroscience candidates developed through partnerships with large pharma. Comparable as a CNS-focused clinical developer with similar regulatory, endpoint, and commercialization risk profile.

TypeEmerging player
Description

Small clinical-stage company developing ASD therapies (suramin program). Most directly comparable peer in terms of size, stage, and ASD focus, though pursuing a different mechanism. Useful for ASD-specific clinical and regulatory benchmarking.

8Curemark
TypeEmerging player
Description

Small clinical-stage company developing CM-AT for autism. Comparable as a niche, autism-focused therapeutics developer, providing a reference point for clinical execution and capital-raising trajectory in the ASD category.

TypeBroad incumbent
Description

Developed xanomeline/trospium for CNS indications (schizophrenia) and acquired by Bristol Myers Squibb in 2024 for $14B. Relevant precedent for the value-accretion curve a CNS biotech can achieve from Phase 3 readiness through commercial scale-out via large-pharma acquisition.

TypeBroad incumbent
Description

CNS specialty pharma (Caplyta for schizophrenia and bipolar depression) acquired by AbbVie for $8.7B in 2024. Comparable trajectory — small-cap CNS developer that scaled through late-stage clinical development into a CNS specialty commercial franchise, then large-pharma exit.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yamo Pharmaceuticals

Autism Spectrum Disorder Therapeuticsyamopharma.com

Yamo Pharmaceuticals is a clinical-stage biopharmaceutical company developing L1-79, an oral selective tyrosine hydroxylase inhibitor aimed at core social-interaction deficits in Autism Spectrum Disorder, currently advancing to Phase 3 with FDA Fast Track Designation.

What Yamo Pharmaceuticals does

Yamo Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in New York, NY. The company is developing L1-79, an investigational oral, twice-daily selective tyrosine hydroxylase inhibitor designed to address core social-interaction deficits in Autism Spectrum Disorder (ASD) — an indication for which there are currently zero FDA-approved therapies. L1-79 modulates catecholamine pathways governing mood, attention, motor skills, and social behavior, and also addresses the hyperactive CNS state often observed in autism by engaging systems that regulate brain function and gut mechanisms implicated in some forms of the disorder. The molecule is described as the only drug in the world developed solely to treat the core symptoms of autism, distinguishing it from therapies that address only peripheral behaviors.

The company completed a multi-center, randomized, double-blind, placebo-controlled crossover Phase 2 study (Y202) in 58 adolescents and young adults with ASD in June 2024, reporting a 7.94-point improvement on the Vineland-3 Socialization Standard Score versus placebo (p=0.0115) — described as the most substantial reported to date with any ASD medication — with statistically significant gains on CGI-S and CGI-3P measures. L1-79 has received FDA Fast Track Designation, and the company is now preparing for Phase 3 development. Yamo is led by an experienced management team including CEO Chuck Bramlage (formerly of Pearl Therapeutics, Covidien, Valeant, Merck, GSK), CMO Dr. Tom Megerian, SVP Regulatory Dr. Tracy Fischer, and CAO Eugene Prahin, supported by a Scientific Advisory Board of prominent autism researchers from Duke, Harvard, Columbia, Emory, and other leading institutions.

Yamo operates as a pre-revenue company with no commercialized product. Its business model is traditional biopharmaceutical: upon FDA approval, the company intends to generate revenue through prescription sales of L1-79, distributed via specialty pharmacies and standard pharmaceutical supply chains targeting healthcare providers and ASD specialists. Marketing and stakeholder engagement are conducted primarily through peer-reviewed publications, scientific conference presentations (INSAR, CNS), and corporate communications, rather than consumer-facing channels. The company has a single disclosed funding event — a capital investment from The Autism Impact Fund in November 2021 — and has 1-10 employees, reflecting its lean, development-stage operational footprint.

Yamo Pharmaceuticals firmographics

Firmographics
Name
Yamo Pharmaceuticals
Legal name
Yamo Pharmaceuticals
Website
https://yamopharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Yamo Pharmaceuticals is a clinical-stage biopharmaceutical company developing L1-79, an oral selective tyrosine hydroxylase inhibitor aimed at core social-interaction deficits in Autism Spectrum Disorder, currently advancing to Phase 3 with FDA Fast Track Designation.
Ownership category
akta.pro rank

Yamo Pharmaceuticals industry classification

Industry
Product category
Autism Spectrum Disorder Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Autism pharmaceutical therapy
  • Clinical-stage biopharmaceutical
  • Selective tyrosine hydroxylase inhibitor
  • CNS drug development
  • Autism spectrum disorder treatment

Where Yamo Pharmaceuticals is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Yamo Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Yamo Pharmaceuticals is a pre-revenue biopharmaceutical company developing L1-79 for Autism Spectrum Disorder. Once FDA approved, the company will generate revenue through prescription pharmaceutical sales of its oral, twice-daily treatment targeting core ASD symptoms. Revenue model will be traditional pharmaceutical product sales with potential for specialty pharmacy distribution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Yamo Pharmaceuticals product offering

Product offering

Core offering

Yamo Pharmaceuticals develops L1-79, an investigational oral twice-daily selective tyrosine hydroxylase inhibitor designed to address core social-interaction deficits in Autism Spectrum Disorder. The company is advancing this single-asset candidate through Phase 3 clinical development with FDA Fast Track Designation, targeting adolescents and young adults diagnosed with ASD.

Product overview

Yamo Pharmaceuticals is a single-product pharmaceutical company developing L1-79 as its lead and only product candidate. L1-79 is an investigational oral drug for Autism Spectrum Disorder (ASD) — the only therapy in the world solely focused on treating core autism symptoms rather than peripheral behaviors. The company operates with a pipeline model advancing L1-79 through clinical stages (Phase 2 complete, Phase 3 anticipated). No platform architecture, modules, or additional products are offered.

Differentiator

Problem solved

Functional benefit

Products and services

  • L1-79

Quantifiable outcome

  • 7.94-point Vineland-3 Socialization Standard Score improvement vs. placebo (p=0.0115) in Phase 2 study
  • +2 more outcomes

Companies that use Yamo Pharmaceuticals

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Yamo Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Yamo Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Yamo Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Specialty CNS pharmaceutical company with an ADHD and neurology portfolio. Comparable to Yamo as a late-stage clinical-to-commercial CNS developer with similar GTM motion into specialty prescribers, though Jazz has a broader marketed product base.
  • Acadia Pharmaceuticals: CNS specialty pharma focused on neurological and psychiatric disorders (pimavanserin franchise). Highly comparable business model — clinical-stage-to-commercial CNS developer with a similar specialty-pharmacy/specialist-prescriber launch approach and small-cap CNS positioning.
  • Axsome Therapeutics: Clinical-stage-to-commercial CNS biotech (Auvelity, Sunosi). Closely analogous to Yamo in scale and trajectory: small team, single-disease focus, pivotal-trial-driven valuation, and a CNS regulatory pathway with Fast Track/priority review experience.
  • Sage Therapeutics: Clinical-stage CNS biotech with FDA-approved Zurzuvae (postpartum depression) and a pipeline focused on neurological/psychiatric indications. Comparable as a CNS-pure-play clinical developer facing similar subjective-endpoint and CNS launch challenges.
  • Supernus Pharmaceuticals: Specialty CNS pharma with ADHD and neurology franchises. Comparable commercial motion (specialty physician sales, specialty pharmacy distribution) and life-cycle trajectory from clinical CNS developer to CNS specialty commercial player.
  • Neumora Therapeutics: Clinical-stage CNS biotech with a pipeline of neuroscience candidates developed through partnerships with large pharma. Comparable as a CNS-focused clinical developer with similar regulatory, endpoint, and commercialization risk profile.

Emerging players

  • PaxMedica: Small clinical-stage company developing ASD therapies (suramin program). Most directly comparable peer in terms of size, stage, and ASD focus, though pursuing a different mechanism. Useful for ASD-specific clinical and regulatory benchmarking.
  • Curemark: Small clinical-stage company developing CM-AT for autism. Comparable as a niche, autism-focused therapeutics developer, providing a reference point for clinical execution and capital-raising trajectory in the ASD category.

Broad incumbents

  • Karuna Therapeutics: Developed xanomeline/trospium for CNS indications (schizophrenia) and acquired by Bristol Myers Squibb in 2024 for $14B. Relevant precedent for the value-accretion curve a CNS biotech can achieve from Phase 3 readiness through commercial scale-out via large-pharma acquisition.
  • Intra-Cellular Therapies: CNS specialty pharma (Caplyta for schizophrenia and bipolar depression) acquired by AbbVie for $8.7B in 2024. Comparable trajectory — small-cap CNS developer that scaled through late-stage clinical development into a CNS specialty commercial franchise, then large-pharma exit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Yamo Pharmaceuticals social profiles

Digital presence

Yamo Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yamo Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Yamo Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yamo Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yamo Pharmaceuticals

What does Yamo Pharmaceuticals do?

Yamo Pharmaceuticals develops L1-79, an investigational oral twice-daily selective tyrosine hydroxylase inhibitor designed to address core social-interaction deficits in Autism Spectrum Disorder. The company is advancing this single-asset candidate through Phase 3 clinical development with FDA Fast Track Designation, targeting adolescents and young adults diagnosed with ASD.

Is Yamo Pharmaceuticals a public or private company?

Yamo Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Yamo Pharmaceuticals founded?

Yamo Pharmaceuticals was founded in 2015. It employs 1 to 10 people.

Where is Yamo Pharmaceuticals based?

Yamo Pharmaceuticals is headquartered in New York, United States, in the North America region.

How does Yamo Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Yamo Pharmaceuticals's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Acadia Pharmaceuticals, Axsome Therapeutics, Sage Therapeutics, Supernus Pharmaceuticals and Neumora Therapeutics. Emerging players are PaxMedica and Curemark. Broad incumbents are Karuna Therapeutics and Intra-Cellular Therapies.

Does Yamo Pharmaceuticals have an API?

No public API is recorded for Yamo Pharmaceuticals.

What industry is Yamo Pharmaceuticals in?

Yamo Pharmaceuticals's product category is Autism Spectrum Disorder Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireYamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family InterestYamo Pharmaceuticals announced over 6,000 inquiries from families in 90+ countries for its Phase 3 trial of L1-79, an investigational drug for autism core symptoms. The company opened a registration site to speed enrollment, with Phase 3 planned in early 2027. L1-79 is the only candidate advancing to Phase 3 for core autism symptoms.New York PostDad: Autism ‘miracle drug’ drastically improved my son’s symptomsA father reported his son Lev's severe autism symptoms improved dramatically after taking Yamo Pharmaceuticals' investigational drug L1-79, which he received via the FDA's expanded-access program. Phase 2 trials showed unprecedented gains in socialization and communication, but the company needs $75 million to advance to Phase 3. The father is personally investing and launching an autism-focused ETF.GlobeNewswireYamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025Yamo Pharmaceuticals presented positive Phase 2 results for L1-79 at INSAR 2025, showing a 7.94-point advantage over placebo on the Vineland-3 Socialization Standard Score in a 12-week study of 58 participants. The drug also improved caregiver and investigator ratings, with no serious adverse events. The company is moving into Phase 3 planning and FDA discussions.GlobeNewswireYamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of AutismYamo Pharmaceuticals announced positive topline results from its Phase 2 trial of L1-79 for autism, showing a statistically significant 7.09-point improvement on the Vineland-3 Socialization standard score versus placebo. The company plans to discuss Phase 3 plans with the FDA and seek Breakthrough Therapy designation.GlobeNewswireYamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum DisorderYamo Pharmaceuticals completed enrollment in its Phase 2 study of L1-79 for autism spectrum disorder in adolescents and young adults. Top-line data are expected in August 2024, and the company has initiated a Phase 3 readiness program. The study evaluated the drug's effect on core social-communication deficits.GlobeNewswireYamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum DisorderYamo Pharmaceuticals announced the first patient enrolled in a Phase 2 study of L1-79 for autism spectrum disorder at six U.S. centers. The placebo-controlled crossover trial will enroll 50 adolescents and adults, testing 200 mg and 300 mg doses over 12-week periods. The study aims to evaluate effects on core social-communication deficits.GlobeNewswireYamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum DisorderYamo Pharmaceuticals received a capital investment from The Autism Impact Fund to support a Phase 2 study of L1-79 in adolescents and adults with autism spectrum disorder. The study, starting in Q4, will randomize patients to two doses or placebo and evaluate social-communication endpoints. L1-79, a tyrosine hydroxylase inhibitor, showed trends for improvement in prior studies.GlobeNewswireYamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum DisorderYamo Pharmaceuticals announced a capital investment from The Autism Impact Fund to support its Phase 2 clinical study of the drug L1-79 for autism spectrum disorder. As part of this transaction, Ashok Srinivasan joined Yamo's board of directors to assist with the upcoming trial involving approximately 50 adolescents and young adults. The Phase 2 study is scheduled to begin in the fourth quarter of 2021.